344 related articles for article (PubMed ID: 25572747)
1. Bradykinin B2 receptor antagonist off label use in short-term prophylaxis in hereditary angioedema.
Angeletti C; Angeletti PM; Mastrobuono F; Pilotti L; Ciccozzi A; Guetti C
Int J Immunopathol Pharmacol; 2014; 27(4):653-9. PubMed ID: 25572747
[TBL] [Abstract][Full Text] [Related]
2. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O;
Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
[TBL] [Abstract][Full Text] [Related]
3. Icatibant as acute treatment for hereditary angioedema in adults.
Farkas H
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):779-88. PubMed ID: 27123689
[TBL] [Abstract][Full Text] [Related]
4. First report of icatibant treatment in a pregnant patient with hereditary angioedema.
Farkas H; Kőhalmi KV; Veszeli N; Tóth F; Varga L
J Obstet Gynaecol Res; 2016 Aug; 42(8):1026-8. PubMed ID: 27093898
[TBL] [Abstract][Full Text] [Related]
5. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.
Caballero T; Aberer W; Longhurst HJ; Maurer M; Zanichelli A; Perrin A; Bouillet L; Andresen I;
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1214-1222. PubMed ID: 28370444
[TBL] [Abstract][Full Text] [Related]
6. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
Hide M; Horiuchi T; Ohsawa I; Andresen I; Fukunaga A
Allergol Int; 2021 Jan; 70(1):45-54. PubMed ID: 32919903
[TBL] [Abstract][Full Text] [Related]
7. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A
Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.
Maurer M; Bork K; Martinez-Saguer I; Aygören-Pürsün E; Botha J; Andresen I; Magerl M
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):163-169. PubMed ID: 30176179
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
Otani IM; Lumry WR; Hurwitz S; Li HH; Craig TJ; Holtzman NS; Iandoli MI; Tucker J; Riedl MA; Zuraw BL; Banerji A
J Allergy Clin Immunol Pract; 2017; 5(2):442-447.e1. PubMed ID: 27818136
[TBL] [Abstract][Full Text] [Related]
10. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
Farkas H; Reshef A; Aberer W; Caballero T; McCarthy L; Hao J; Nothaft W; Schranz J; Bernstein JA; Li HH
J Allergy Clin Immunol Pract; 2017; 5(6):1671-1678.e2. PubMed ID: 28601641
[TBL] [Abstract][Full Text] [Related]
11. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
Lumry WR; Farkas H; Moldovan D; Toubi E; Baptista J; Craig T; Riedl M
Int Arch Allergy Immunol; 2015; 168(1):44-55. PubMed ID: 26556097
[TBL] [Abstract][Full Text] [Related]
12. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.
Hernández Fernandez de Rojas D; Ibañez E; Longhurst H; Maurer M; Fabien V; Aberer W; Bouillet L; Zanichelli A; Caballero T;
Int Arch Allergy Immunol; 2015; 167(1):21-8. PubMed ID: 26112099
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study.
Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
Allergol Int; 2020 Apr; 69(2):268-273. PubMed ID: 31672405
[TBL] [Abstract][Full Text] [Related]
14. Self-administration of icatibant in acute attacks of Type I hereditary angioedema: A case report and review of hereditary angioedema.
Piras V; Alves F; Gonçalo M
Dermatol Ther; 2019 Nov; 32(6):e13098. PubMed ID: 31579975
[TBL] [Abstract][Full Text] [Related]
15. Switch to icatibant in a patient affected by hereditary angioedema with high disease activity: a case report.
Firinu D; Barca MP; Serusi L; Lorrai MM; Peralta MM; Manconi PE; Del Giacco SR
Int J Immunopathol Pharmacol; 2012; 25(1):269-73. PubMed ID: 22507340
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging therapies to prevent hereditary angioedema attacks.
Lumry WR
Am J Manag Care; 2018 Aug; 24(14 Suppl):S299-S307. PubMed ID: 30132644
[TBL] [Abstract][Full Text] [Related]
17. An evidence based therapeutic approach to hereditary and acquired angioedema.
Bork K
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294
[TBL] [Abstract][Full Text] [Related]
18. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
[TBL] [Abstract][Full Text] [Related]
19. HAE update: determining optimal patient specific therapy.
Gower RG
Allergy Asthma Proc; 2013; 34(1):7-12. PubMed ID: 23406928
[TBL] [Abstract][Full Text] [Related]
20. Icatibant for hereditary angioedema.
Gras J
Drugs Today (Barc); 2009 Dec; 45(12):855-64. PubMed ID: 20135020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
